Everything below concerns lipolysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-13. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The company was co-founded in 1988 by Donald and Susan Sutherland, who sought ice cream that was neither hard packed nor soft-serve. Cold Stone Creamery opened its first store that year in Tempe, Arizona. The original Cold Stone Creamery, store #0001, remains in operation near the same intersection at the southwest corner of McClintock and Southern in Tempe. The store moved from the original location to this location in the early 1990s. The company has maintained the same concept created by Steve Herrell, who founded Steve's Ice Cream. Patrons select a flavor of ice cream and then choose a number of mix-ins to be added to the ice cream. Mix-ins include candies, nuts, brownies and syrups. Cold Stone derives its name from the frozen granite slab that employees use to fold mix-ins into the ice cream. In 1995, Cold Stone Creamery opened its first franchise store in Tempe, Arizona. Shortly after, a second location was opened, in Camarillo, California. Cold Stone Creamery has become the sixth best-selling brand of ice cream in the US. In 2008, Cold Stone opened its first European franchise in Copenhagen, Denmark. Three more stores were later opened in other parts of the country. In January 2006, the company was named the 11th fastest-growing franchise by Entrepreneur magazine. In June 2009, the company opened its first locations in Canada. As of 2012, three stores had opened in Singapore. In 2012, Cold Stone opened its first store in Nigeria, the first in Sub-Saharan Africa.
The dragonless Aemond claims Vhagar, which leads to a fight between Alicent and Rhaenyra's children where Luke slashes one of Aemond's eyes out. They are all brought before Viserys in a mass gathering, where a furious Alicent demands one of Luke's eyes to be taken out as retribution, arguing with Rhaenyra who defends her kids. After Viserys refuses to abide by Alicent's demand, she grabs his Valyrian steel dagger and rushes towards Luke, but is blocked by Rhaenyra. Aemond asserts that the loss of his eye in exchange for gaining a dragon was a fair trade, and Viserys considers the matter settled under those conditions. He also declares that anyone claiming Rhaenyra's children to be bastards will lose their tongue. Viserys reinstates Otto as his Hand (as Lyonel had recently perished in a fire), where he and Alicent conspire to solidify their family's positions at court while Rhaenyra and Daemon unite to counter their influence over the court. Six years later, Viserys' health has greatly declined, as his face is partially disfigured and he is frequently bedridden. Otto and Alicent have de facto control over royal matters, as Viserys frequently drinks milk of the poppy and has declining mental acuity. Corlys' younger brother Vaemond petitions the crown to be named as Corlys' heir instead of Luke, who he accuses of being a bastard. Otto presides over the matter and is inclined to rule against Luke, but a frail Viserys shows up to the throne room to oversee the matter himself, walking to the Iron Throne with great difficulty and support from Daemon.
=== Courtship === Male courtship in P. phalangioides can be observed in four different steps: abdominal vibrations, tapping of the female's web, web jerking, and tapping the female's legs. In order to mate with the females, the males must perform courtship in a manner which will not result in the female assuming that the male is prey. Otherwise, the male would be attacked. As the males approach the females, they begin to do a series of rapid dorso-ventral vibrations with their opisthosoma. This only occurs once the females have noticed the presence of the males. The males then use the ventral portion of their tarsus to begin tapping on the web of the female. This tapping can last up to twenty minutes as the male inches closer to the female. Then, using claws on their tarsus, the males hook onto the web and perform rapid jerk movements using their legs. On average, this jerking lasts for a few minutes with each jerk lasting less than half of a second. In between sequences of jerking, the males continue to move closer to the females. The males then tap on the female's legs with their cephalothorax positioned downwards for, on average, eight minutes. At this point, receptive females will take on a specific position in which they are motionless with their opisthosoma turned horizontally and their legs extended outward. Before coupling, many of the males will use their pedipalps to cut certain parts of the web closest to the female.
== Properties == The alcohol dehydrogenases comprise a group of several isozymes that catalyse the oxidation of primary and secondary alcohols to aldehydes and ketones, respectively, and also can catalyse the reverse reaction. In mammals this is a redox (reduction/oxidation) reaction involving the coenzyme nicotinamide adenine dinucleotide (NAD+).
Sources: en.wikipedia.org
== Description == Rhodiola rosea is from 5 to 40 centimetres (2.0 to 15.7 in) tall, fleshy, and has several stems growing from a short, scaly rootstock. Flowers have 4 sepals and 4 petals, yellow to greenish yellow in color sometimes tipped with red, about 1 to 3.5 millimetres (0.039 to 0.138 in) long, and blooming in summer. Several shoots growing from the same thick root may reach 5 to 35 centimetres (2.0 to 13.8 in) in height. R. rosea is dioecious – having separate female and male plants.
It is a serious matter if you can just create things that are not right." Arsenal's press officer Clare Tomlinson, who was present at the news conference, recalled Wenger phoning the next day and demanding why he could not take action against the press for printing the story. The culprit responsible for spreading gossip in the City later apologised to Wenger. During this, Arsenal had led the Premier League, but poor form in February 1997 caused Wenger to rule out his team's chances of winning the title. They finished third in his first season, missing out on UEFA Champions League qualification to Newcastle United on goal difference – the tiebreaker used to determine the ranking between teams equal on points.
== Censorship == During the conflict, the Taliban's intelligence agency, the General Directorate of Intelligence (GDI), ordered Afghan domestic media outlets not to cover areas targeted in recent Pakistani airstrikes. In some cases, intelligence personnel monitored media offices and newsroom operations to enforce the directive, and media outlets were warned against defying the order. Taliban intelligence officials also warned residents against publishing images or details of locations in Afghanistan targeted by Pakistani strikes. Afghan local sources stated that the Taliban were restricting access to information about their own casualties, as well as those among civilians. They added that only Taliban members were allowed to take images of affected areas and victims, making independent verification of casualties and damage difficult. According to the sources, even Taliban controlled media outlets were not allowed to photograph the sites and areas targeted by Pakistan's airstrikes, and there were no accurate statistics on the casualties of civilians and Taliban fighters. On 1 March, the Taliban suspended the broadcasts of Rah-e-Farda radio and television in Kabul, a channel affiliated with Mohammad Mohaqiq. The suspension was linked to remarks by Mohammad Mohaqiq, which reportedly criticized the Taliban's recent retaliatory attacks against Pakistan. On 5 March, the Taliban increased pressure on local media outlets, warning journalists not to report on attacks, particularly those targeting Taliban military sites.
=== Mark Conner-Healy === Mark Conner-Healy is played by Ames McNamara. The younger of Darlene's two children, Mark is a 10-year-old boy with a strong interest in fashion. His interest in things traditionally feminine, such as wearing makeup and skirts, is somewhat worrisome to his grandparents, with Roseanne worried that Mark will be bullied by his narrow-minded peers and Dan feeling that he needs to persuade the youngster to take on more masculine traits. Noticing a classmate make a snide comment to Mark on his first day at school in Lanford, Roseanne threatens his classmates by telling them she is a witch, while Dan gives Mark a pocket knife, which ultimately results in him being called to the principal's office and sent home from school for the day, much to Darlene's chagrin. Despite Roseanne and Dan's concerns, they express support and love for him. Mark is named after his deceased uncle, Mark Healy.
In the glycolytic pathway, 1,3-bisphosphoglycerate is dephosphorylated to form 3-phosphoglyceric acid in a coupled reaction producing two ATP via substrate-level phosphorylation. The single phosphate group left on the 3-PGA molecule then moves from an end carbon to a central carbon, producing 2-phosphoglycerate. This phosphate group relocation is catalyzed by phosphoglycerate mutase, an enzyme that also catalyzes the reverse reaction.
Sources: en.wikipedia.org
The most common method for alkylation of the lactam nitrogen of 2,5-diketopiperazines is based on the use of sodium hydride as base. However epimerisation can occur especially with proline-fused 2,5-diketopiperazines, even with milder methods such as under phase-transfer catalyst conditions for example 1 to 2. Reduction of the carbonyl groups of chiral 2,5-diketopiperazine with lithium aluminium hydride (LiAlH4) cleanly gives the corresponding chiral piperazines. For example, cyclo(L-Phe-L-Phe) 1 gives the chiral piperazine (2S,5S)-dibenzylpiperazine 2. Reaction of the lactam-derived enol phosphates 4 of 2,5-diketopiperazines with palladium catalyzed reactions (reduction, Suzuki and Stille cross-coupling reactions) enables the synthesis of a range of functionalised 1,4-dihydropyrazines 5 which can be aromatized to 1,4-pyrazines 6 in the presence of acid.
Equine chorionic gonadotropin Gonadotropin preparations Human placental lactogen Pregnancy hormones Triple test, a screening test in pregnancy The Weight-Loss Cure "They" Don't Want You to Know About, a book written by Kevin Trudeau Chorionic+Gonadotropin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "History of pregnancy test". U.S. National Institutes of Health. Archived from the original on 2011-01-13. Retrieved 2011-01-10.
The few (largely space based) applications for RTGs that still exist are largely supplied by 238Pu despite its higher cost, as it has a higher power density, longer half-life and is easier shielded since it is an alpha emitter while strontium-90 is a beta emitter.
=== Stops and searches === A 2015 report conducted by the US Department of Justice found that black drivers in Ferguson, Missouri, were over twice as likely to be searched during vehicle stops but were found in possession of contraband 26% less often than white drivers. A 2016 report conducted by the San Francisco District Attorney's Office concluded that racial disparities exist regarding stops, searches, and arrests by the San Francisco Police Department and that the disparities were especially salient for the black population. Blacks made up almost 42% of all non-consensual searches after a stop but accounted for fewer than 15% of all stops in 2015. Of all people searched without consent, Black and Hispanic people had the lowest "hit rates" (i.e., the lowest rate of contraband recovered). A 2016 Chicago Police Accountability Task Force report found that black and Hispanic drivers were searched by the Chicago Police more than four times more frequently than white drivers, but white drivers were found with contraband twice as often as black and Hispanic drivers.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.